Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
Interpace Biosciences will effect a 1-for-5 reverse stock split effective August 27, 2026, reducing outstanding shares from approximately 27.7 million to 5.5 million. The split is primarily intended to bring the company into compliance with the minimum bid price requirement for listing on the Nasdaq Capital Market, although listing is not guaranteed.
Key figures
- Reverse split ratio
- 1-for-5
- Shares outstanding pre split
- 27.7 million
- Shares outstanding post split
- 5.5 million
- Nasdaq market value requirement
- $15 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.